Atomwise, formerly known as Chematria, is a biotech company that develops artificial intelligence systems using powerful deep learning algorithms and supercomputers for drug discovery.
Atomwise uses artificial intelligence to help discover new medicines and agricultural compounds. Its groundbreaking AtomNet technology reasons like a human chemist, using powerful deep learning algorithms and supercomputers to analyze millions of potential molecules each day.
Atomwise was founded in 2012 by Abraham Heifets & Izhar Wallach. The company was formerly known as Chematria, Inc. and changed its name to Atomwise, Inc. in 2015. Atomwise has it's headquartered based in San Francisco, California.
Atomwise predicts drug candidates for pharmaceutical companies, startups, and research institutions. It's AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve.
Atomwise has partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.
Atomwise has already signed contracts worth $5.5 billion with corporate partners that include Eli Lilly & Co., Bayer, Hansoh Pharmaceuticals and Bridge Biotherapeutics. Smaller, earlier-stage companies like StemoniX and SEngine Precision Medicine are also using Atomwise’s tech.
Atomwise is backed by Monsanto Growth Ventures (MGV), B Capital, Sanabil Investments, Khosla Ventures, Tencent Holdings, Y Combinator, DCVC, BV, AME Cloud Ventures and others. The company raised raised $123M in Series B round on Aug 11, 2020. This brings Atomwise's total funding to $174.3M to date.